Thalia Therapeutics feature in recent article about exciting potential of RNA-based gene silencing therapies

This Fierce Biotech article highlights the exciting potential of RNA-based gene silencing therapies to treat previously "undruggable" targets, particularly a serious cardiovascular target and risk factor called Lp(a), which is prevalent at dangerous levels in up to 20% of the population. LP(a) is set genetically at birth and does not reduce with exercise, diet or weight loss. High levels of LP(a) are correlated with a significant increased risk of cardiovascular events.

At Thalia Therapeutics, we are focused on addressing this unmet need with a dual-acting siRNA approach designed to inhibit both Lp(a) and PCSK9, two independent cardiovascular targets and risk factors.

CEO David Solomon commented: “The dual-acting medicine is a really strong approach,” highlighting the growing momentum behind combination therapies to drive greater efficacy in complex diseases.

As the science matures, companies targeting high-value indications like cardiovascular disease with differentiated, platform-driven approaches stand to capture significant value.

Read more: https://lnkd.in/gayG9vFn